Design Therapeutics, Inc. is a clinical-stage biotechnology company that researches and develops disease-modifying therapies for severe genetic disorders. Headquartered in Carlsbad, California, the company leverages its proprietary GeneTAC (gene targeted chimera) platform to design small molecules that can either upregulate or downregulate the transcription of specific genes, addressing the root causes of inherited diseases. Its lead clinical programs include DT-216P2 for the treatment of Friedreich ataxia, DT-168 for Fuchs endothelial corneal dystrophy, and DT-818 for myotonic dystrophy type-1. Additionally, the company is advancing discovery-stage efforts for other monogenic conditions, including Huntington's disease. By focusing on nucleotide repeat expansion disorders, Design Therapeutics aims to restore normal cellular function and provide novel genomic medicines to patients with limited treatment options.
